Qiagen
The tools labs use to read genetic material and detect disease.
52-week range
As of 5 Oct 2026, 17:36What does Qiagen do?
Qiagen makes tests and instruments that labs use to extract and analyse genetic material (DNA and RNA) from samples. That helps detect infections, tuberculosis or cancer markers. Its customers are hospitals, labs, researchers and drug companies. It was founded in Düsseldorf in 1984, is legally based in the Netherlands and has its largest site in Hilden, Germany.
When your blood sample is tested for tuberculosis or a swab is checked for germs, the lab often uses Qiagen tests.
How Qiagen makes money
- Diagnostic tests38 %
- Sample preparation32 %
- PCR tests & instruments15 %
- Genome sequencing12 %
- Other4 %
Strengths
- About 90% of revenue comes from consumables and related services that labs keep reordering.
- The market leader in preparing DNA and RNA samples.
- Its QuantiFERON blood test is replacing the older tuberculosis skin test in many countries.
Risks
- Cuts in research funding, especially in the US, hurt demand.
- Strong, much larger competitors such as Thermo Fisher and Roche.
- New instruments can fail: the NeuMoDx system was discontinued in 2024.
- Founded
- 1984
- Headquarters
- Venlo (NL) and Hilden, Germany
- Employees
- about 5,700
What if you had invested in Qiagen earlier?
Similar stocks
+19.9%Merck
The world’s oldest pharma and chemicals company, since 1668.
-22.9%Siemens Healthineers
MRI, CT and cancer therapy: medical technology from Erlangen.
+34.3%Johnson & Johnson
Medicines and medical technology for hospitals worldwide.
-12.3%Fresenius
Hospitals and IV drips from Bad Homburg.
This page explains the company and is not a recommendation to buy or sell.